Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 February 2004, Vol. 103, No. 4, pp. 1475-1484.
Prepublished online as a Blood First Edition Paper on October 23, 2003; DOI 10.1182/blood-2003-06-2116.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-06-2116v1
2003-06-2116v2
103/4/1475    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenwald, R. J.
Right arrow Articles by Denis, G. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenwald, R. J.
Right arrow Articles by Denis, G. V.
Related Collections
Right arrow Cell Cycle
Right arrow Oncogenes and Tumor Suppressors
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Eµ-BRD2 transgenic mice develop B-cell lymphoma and leukemia

Rebecca J. Greenwald, Joseph R. Tumang, Anupama Sinha, Nicolas Currier, Robert D. Cardiff, Thomas L. Rothstein, Douglas V. Faller, and Gerald V. Denis

From the Department of Pathology, Immunology Research Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Immunobiology Unit, Departments of Medicine and Microbiology, Evans Biomedical Research Center, Boston Medical Center, Boston, MA; Cancer Research Center, Boston University School of Medicine, Boston, MA; and Center for Comparative Medicine, University of California at Davis, Davis, CA.

Transgenic mice with lymphoid-restricted overexpression of the double bromodomain protein bromodomain-containing 2 (Brd2) develop splenic B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and lung. Brd2 is a nuclear-localized transcription factor kinase that is most closely related to TATA box binding protein–associated factor, 250 kDa (TAFII250) and the Drosophila developmental protein female sterile homeotic. Constitutive expression of BRD2 in the lymphoid compartment increases cyclin A transcription, "priming" transgenic B cells for proliferation. Mice stochastically develop an aggressive B-cell lymphoma with the features of B-1 cells, including CD5 and surface IgM expression. The B-cell lymphoma is monoclonal for immunoglobulin gene rearrangement and is phenotypically stable. The lymphoblasts are very large and express a transcriptome that is similar to human non-Hodgkin lymphomas. Both a wild-type BRD2 transgene and a kinase-null point mutant drive lymphomagenesis; therefore we propose that, rather than kinase activity, Brd2-mediated recruitment of E2 promoter binding factors (E2Fs) and a specific histone acetyltransferase to the cyclin A promoter by both types of transgene is a mechanistic basis for neoplasia. This report is the first to describe a transgenic mouse model for constitutive expression of a protein with more than one bromodomain.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. E. Lenburg, A. Sinha, D. V. Faller, and G. V. Denis
Tumor-specific and Proliferation-specific Gene Expression Typifies Murine Transgenic B Cell Lymphomagenesis
J. Biol. Chem., February 16, 2007; 282(7): 4803 - 4811.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Ottinger, T. Christalla, K. Nathan, M. M. Brinkmann, A. Viejo-Borbolla, and T. F. Schulz
Kaposi's Sarcoma-Associated Herpesvirus LANA-1 Interacts with the Short Variant of BRD4 and Releases Cells from a BRD4- and BRD2/RING3-Induced G1 Cell Cycle Arrest
J. Virol., November 1, 2006; 80(21): 10772 - 10786.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
H. Longe, D. V. Faller, and G. V. Denis
Telomere-Based Pre-Clinical Therapy in a Murine Model of Non-Hodgkin's Lymphoma of the Diffuse Large B Cell (DLCL)Type.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 607 - 607.
[Abstract]

Home page
 BloodHome page
U. Modlich, O. S. Kustikova, M. Schmidt, C. Rudolph, J. Meyer, Z. Li, K. Kamino, N. von Neuhoff, B. Schlegelberger, K. Kuehlcke, et al.
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis
Blood, June 1, 2005; 105(11): 4235 - 4246.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020